• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Harlan Levine, principal, Towers Perrin

Article

Currently, Harlan Levine, MD, is the only benefits consultant to have experience on the buy and sell side of disease management on a national basis.

Harlan Levine, MD
Principal
Towers Perrin

Currently, he is the only benefits consultant to have experience on the buy and sell side of disease management on a national basis. Through his previous role at OptumHealth, he helped UnitedHealth Group become the only national health plan to receive DMPC certification for savings measurement validity, and one of just four to be honored by HIRC for overall program excellence in 2008-the only benefits consultant to have taken an organization through both processes successfully.

Dr. Levine is a graduate of Harvard College, where he earned a B.A. degree in biology, and of the University of California, San Francisco School of Medicine. He is a member of the DMAA: The Care Continuum Alliance's (DMAA) board of directors and government affairs committee.

Related Content
© 2024 MJH Life Sciences

All rights reserved.